Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma-Reference-Cited by-同舟云学术

Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma

Published:2019-06-09 Issue:6 Volume:186 Page:845-854
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Spurgeon Stephen E.¹^ORCID,Sharma Kamal²³,Claxton David F.²,Ehmann Christopher²,Pu Jeffrey⁴,Shimko Sara²,Stewart August²,Subbiah Nan¹,Palmbach Gundula¹,LeBlanc Francis⁵^ORCID,Latour Emile⁵,Chen YiYi⁶,Mori Motomi⁶,Hasanali Zainul²,Epner Elliot M.²⁷

Affiliation:

1. Center for Hematologic Malignancies Knight Cancer Institute at Oregon Health & Science University Portland ORUSA

2. Penn State Hershey Cancer Institute Hershey PAUSA

3. Cassidy Cancer Center Winter Haven FLUSA

4. Upstate Cancer Center, SUNY Upstate Medical University Syracuse NY USA

5. Cincinnati Children’s Hospital Medical Center Cincinnati OHUSA

6. Biostatistics Shared Resource Oregon Health and Science University Portland ORUSA

7. Enloe Medical Center Chico CA USA

Funder

Merck

Publisher

Wiley